IrelandIreland

Elan keeps faith in Alzheimer drug

11.08.2010

Elan Corporation plans to advance ELND005 into phase III testing, despite data indicating that it missed the co-primary endpoints in a phase II AD201 trial for Alzheimer's. According to the trial results, ELND005, a small molecule that disaggregates beta amyloid fibrils, failed to significantly improve cognitive and functional measures for up to 18 months. However, the Irish biotech company and its partner Transition Therapeutics have said that the drug appeared safe, and had a biological effect on the amyloid-beta protein in the cerebrospinal fluid. Analysts think that the two companies will be looking for a further partner to share risk before embarking on a costly phase III study. Elan also recently opted to put off a sale or spin-off for its drug delivery unit.
The final analysis of the finished phase II trial excluded all 180 patients from the 1,000 and 2,000 mg high-dose groups. The partners discontinued these groups last year following an analysis by an independent safety monitoring committee that showing a higher rate of serious adverse events in the cohorts, including nine deaths. Rates of serious adverse events for 250 mg ELND005 and placebo were 21.6% and 13.3%, respectively, while rates of serious adverse events thought to be treatment-related were 2.3% and 2.4%, respectively.

IrelandIreland

20.03.2012

While on a trip to strengthen economic ties between Ireland and California, Ireland's minister for jobs, enterprise and innovation, Richard Bruton, revealed on 15 March that two Irish government organisations have provided...

IrelandIreland

16.03.2012

Dublin – Irish drugmaker Shire plc has agreed to pay US-$100m in upfront for Ferrokin Biosciences Inc., a San Francisco-based specialist for iron chelation therapies. US-$225m could be added if certain milestones are achieved....

IrelandIreland

07.03.2012

Abbott Laboratories is to spend a85m and expand its pharmaceutical manu­facturing facility in Sligo (Ireland), saying that would help the company to ensure its supply of compounds in bio­pharmaceutical areas like virology and...

IrelandIreland

24.01.2012

Weston/Dublin - The focus for Tysabri, the MS drug jointly developed by Irish Elan and US-Biogen, has become a little more accurate. The US Food and Drug Administration (FDA) stated that the occurrence of antibodies against the...

IrelandIreland

13.12.2011

Dublin/Cambridge – The University of Cambridge and Irish drugmaker Elan Pharmaceutical Inc. have joined forces in the battle against Alzheimer’s Disease. Together, the two will create the Cambridge-Elan Centre for Research...

IrelandIreland

07.12.2011

Uppsala/Craigavon - Irish Almac trusts a Swedish platform to develop new cancer drug candidates. As Uppsala-based Beactica announced on Tuesday, its Sprint-technology will be used to identify fragment hits against a number of...

IrelandIreland

05.12.2011

Dublin /New York – Irish Tibotec Pharmaceutical Ltd and Bristol-Myers Squibb (BMS) have entered into a clinical collaboration for the treatment of chronic hepatitis C infections with a combination of BMS’ NS5A replication complex...

IrelandIreland

01.10.2011

Athlone – Biopharma group Alkermes has established its new Irish corporate base following its merger with Elan Drug Tech­nologies. The a712m (US$960m) deal agreed back in May – which saw Alkermes acquire Elan’s Athlone-based drug...

Displaying results 1 to 10 out of 49

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-ireland/article/elan-keeps-faith-in-alzheimer-drug.html

Print Magazine

Product of the week

Products

Events

All Events

Stock list

All quotes

TOP

    FLOP

      TOP

        FLOP

          TOP

            FLOP

              No liability assumed, Date: 26.11.2014

              Current issue

              All issues